This is a working overview of HGF mimetic, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
==== Established in the first team ==== Now back at Tottenham, Townsend started the second Premier League match of their 2013–14 season, and went on to make a total of 33 appearances, including 25 in the league. He scored twice, in a 5–0 away victory over Dinamo Tbilisi in the Europa League (his first match of the season), and his first in the Premier League in a 2–0 victory away to Aston Villa on 20 October 2013. In the middle of the season, Townsend came under the management of his third Tottenham boss, after Villas-Boas was replaced by Tim Sherwood. Sherwood's contract was terminated at the end of the season, and Townsend started the 2014–15 season under new manager Mauricio Pochettino. He made a total of 35 appearances, scoring five goals, but was reduced to just 17 appearances in the league, having been unable to hold down a starting place until the second half of the season. He started as Tottenham lost 2–0 to Chelsea in the 2015 League Cup Final at Wembley Stadium on 1 March. Having had nine loan spells, Townsend's career path to regular first team football for Tottenham is often discussed in the context of a wider debate in English football about the best way to develop young talent, contrasting the loan route with Premier League players being developed in Under-21 leagues, or being brought to the Premier League level via transfers from lower league clubs.
== Prognosis == A 2018 study placed 10-year survival rates at 88%, without differentiation based on subtype. Diffuse systemic sclerosis, internal organ complications, and older age at diagnosis are associated with worse prognoses.
=== Suicide === The gabapentin prescribing information contains a warning of an increased risk of suicidal thoughts and behaviors. The warning is based on a meta-analysis of all approved antiepileptic drugs in 2008, and not with gabapentin alone. According to an experimental meta-analysis of insurance claims databases, gabapentin use is associated with an approximately 40% increased risk of suicide, suicide attempt, and violent death as compared with a reference anticonvulsant drug topiramate. The risk is increased for people with bipolar disorder or epilepsy. Another study has shown an approximately doubled rate of suicide attempts and self-harm in people with bipolar disorder who are taking gabapentin versus those taking lithium. A large Swedish study suggests that gabapentinoids are associated with an increased risk of suicidal behavior, unintentional overdoses, head/body injuries, and road traffic incidents and offenses. On the other hand, a study published by the Harvard Data Science Review found that gabapentin was associated with a significantly reduced rate of suicide. In addition, a 2010 study published by the Pharmacoepidemiology and Drug Safety journal concluded that although there was no significant suicide rate decrease between the pre-prescription window and the post-prescription window for the non-psychiatric population, significant reductions in suicide rates were observed in psychiatric persons.
Sources: en.wikipedia.org
Pan-Slavism in the south, largely advocated by Serbs, would often turn to Russia for support. The Southern Slavic movement advocated the independence of the Slavic peoples in the Austro-Hungarian Empire, Republic of Venice and the Ottoman Empire. Most Serbian intellectuals sought to unite all of the Southern, Balkan Slavs, whether Catholic (Croats, Slovenes), Muslim (Bosniaks, Pomaks), or Orthodox (Montenegrins, Serbs, Macedonians, Bulgarians) as a "Southern-Slavic nation of three faiths". Austria feared that Pan-Slavists would endanger the empire. In Austria-Hungary Southern Slavs were distributed among several entities: Slovenes in the Austrian part (Carniola, Styria, Carinthia, Gorizia and Gradisca, Trieste, Istria), Croats and Serbs in the Hungarian part within the autonomous Kingdom of Croatia-Slavonia and in the Austrian part within the autonomous Kingdom of Dalmatia, and in Bosnia and Herzegovina, under direct control from Vienna. Owing to a different position within Austria-Hungary, several different goals were prominent among the Southern Slavs of Austria-Hungary. A strong alternative to Pan-Slavism was Austroslavism, especially among the Croats and Slovenes. Because the Serbs were dispersed among several regions, and the fact that they had ties to the independent nation state of Kingdom of Serbia, they were among the strongest supporters of independence of South-Slavs from Austria-Hungary and uniting into a common state under Serbian monarchy.
== General and cited references == Hartwig, Andrea (2013). "Cadmium and Cancer". Cadmium: From Toxicity to Essentiality. Metal Ions in Life Sciences. Vol. 11. pp. 491–507. doi:10.1007/978-94-007-5179-8_15. ISBN 978-94-007-5178-1. PMID 23430782. "Cadmium and you" (PDF). Bootle, UK: Health and Safety Executive. March 2010. Retrieved January 29, 2011. Shannon M. "Heavy Metal Poisoning", in Haddad LM, Shannon M, Winchester JF (editors): Clinical Management of Poisoning and Drug Overdose, Third Edition, 1998.
The aerosol or spallation frangible powder produced by impact and combustion of depleted uranium munitions (or armour) can potentially contaminate wide areas around the impact sites, leading to possible inhalation by human beings. The actual level of acute and chronic toxicity of DU is also controversial. Several studies using cultured cells and laboratory rodents suggest the possibility of leukemogenic, genetic, reproductive, and neurological effects from chronic exposure. A 2005 epidemiology review concluded "In aggregate the human epidemiological evidence is consistent with increased risk of birth defects in offspring of persons exposed to DU." A 2021 study concluded that DU from exploding munitions did not lead to Gulf War illness in American veterans deployed in the Gulf War. A 2011 study found elevated levels of uranium in soil and hair samples from Fallujah, Iraq, but it was from slightly enriched uranium instead of DU.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.